PTC Therapeutics raises 2026 revenue guidance after strong Q1 with $273M total revenue and Sephience growth.

PTC Therapeutics reported $273 million in total revenue for Q1 2026, driven by $226 million in product sales, including $125 million from its Sephience drug, which grew 36% quarter-over-quarter. Positive clinical trial results for votoplam and plans to start a new vatiquinone study support ongoing development efforts. The company raised its full-year 2026 product revenue guidance to $750-$850 million, reflecting strong commercial momentum and expanding global sales. Despite a small net loss in Q1, PTC remains financially robust with nearly $1.9 billion in cash and securities.